A61K49/0404

SYRINGE
20210038803 · 2021-02-11 ·

Described herein are syringe caps including a plug portion and a protruding member extending from one end of the plug portion. The protruding member can extend a length greater than a depth of an accumulated component in the syringe.

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

The application discloses a composition for hard tissue repair comprising a monomer (A), a polymer powder (B) and a polymerization initiator (C), wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, and the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less, as well as, a kit for hard tissue repair comprising three or more members, in which each of the components of the monomer (A), the polymer powder (B) and the polymerization initiator (C) contained in this composition for hard tissue repair are divided and contained in the members in an optional combination.

COLOR-CODED AND SIZED LOADABLE POLYMERIC PARTICLES FOR THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS AND METHODS OFPREPARING AND USING THE SAME

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

A HARDENABLE MULTI-PART ACRYLIC COMPOSITION
20200338231 · 2020-10-29 ·

The invention relates to a hardenable multi-part acrylic composition. The composition has at least two parts which react with each other upon being mixed together to progressively harden to form a solid cement, such as a bone cement. The beads in the first part comprise an acrylic bead polymer core produced by suspension polymerisation and having a Tg of >70 C. and emulsion polymerised acrylic microparticles at least partially coating the surface of the acrylic bead polymer core. The microparticles may form a porous coalesced network. The bone cement composition comprises the first part and a liquid second part and optionally, further parts. The parts are operable to form a cement which hardens to a solid mass upon mixing of the parts together. The composition further comprises an acrylic monomer component in the second part and an initiator component. A method of production of coated beads for the hardenable multipart composition and a solid cement is also described.

TRIGGERABLE HYDROGEL COMPOSITIONS AND RELATED METHODS

Triggerable hydrogel compositions and related methods are generally disclosed. In some embodiments, the compositions and related methods may be used for medical-related or other applications. For example, the compositions and methods described herein may be useful, for example, in biomedical applications such as articles for (e.g., gastric) retention. In some embodiments, methods for deploying and/or removing an article comprising the composition, such as an article for gastric retention, are provided. The article and/or composition may be removed internally from a subject by, for example, introducing at least one reagent (e.g., one reagent, two reagents) such that at least a portion of the composition disassociates. In certain embodiments, the composition comprises a polymer network comprising two or more interpenetrating polymers. In some cases, a first polymer comprises a first cross-link moiety configured to dissociate upon interaction with a reagent. For example, the composition may be administered to a subject such that it is retained at a location internal (e.g., gastric) to the subject. In some embodiments, a reagent may be administered to the subject (e.g., the subject drinks the reagent) such that the reagent interacts with the composition and at least a first cross-link moiety disassociates. In some embodiments, upon disassociation of one or more cross-link moieties of the polymer network, the composition is no longer retained at the location internal to the subject (e.g., dissociates such that it exits the subject). In some cases, the polymer network is configured (e.g., upon administration of the composition to a subject) such that the composition is retained at the location internal to the subject for greater than or equal to 24 hours.

Radio-opaque writing instruments and methods of use
10709800 · 2020-07-14 ·

A radio-opaque composition is formulated to enable a clinician to apply custom markings to a surface, such as a patient's skin or a surgical drape on the patient. More specifically, the radio-opaque composition may be used to write on the surface. The markings may be well-defined and contrast with the surface to which they are applied. Such a composition may include a liquid radio-opaque component that includes one or more radio-opaque materials that have been dissolved in a solvent, as well as a solid radio-opaque component with particles of one or more radio-opaque materials dispersed throughout a carrier, such as the solvent of the liquid radio-opaque component. Marking apparatuses that may be used to write with the radio-opaque composition are also disclosed, as are methods for using the radio-opaque composition.

Method to enhance swallowing safety and appeal of beverages for treating dysphagia based on rheological and sensory parameters

An edible composition of matter having an apparent viscosity of from about 150 cP to about 2000 cP at about 30 s1; a yield stress of from 0 Pa to about 20 Pa at 1 s.sup.1; and a flow index of from about 0.2 to about 0.6. The composition may include an imaging agent. The compositions are useful for providing sustenance to dysphagic subjects and for evalualuating dysphagia.

SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION
20200000959 · 2020-01-02 ·

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.

Syringe
11911588 · 2024-02-27 · ·

Described herein are syringe caps including a plug portion and a protruding member extending from one end of the plug portion. The protruding member can extend a length greater than a depth of an accumulated component in the syringe. Also described herein, are systems including a syringe containing a composition and a syringe cap. The syringe cap can include a luer-lock with a projecting member that projects into the syringe. The projecting member can assist in creating a tunnel through the accumulated material thereby allowing degassing of the composition. The projecting member can also help to prevent accumulation of a radiopaque visualization agent or contrast agent that may accumulate along one end of the syringe.

CALCINEURIN INHIBITOR AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG TO REDUCE RISK OF POST-IMAGING PANCREATITIS

The present invention relates to compositions and methods for targeted administration to the pancreas of a calcineurin inhibitor and a non-steroidal anti-inflammatory drug (NSAID) to reduce the risk and/or limit the extent of post-imaging pancreatitis associated with procedures that employ a radiocontrast medium, particularly procedures that selectively image the pancreas, gallbladder and/or biliary tree.